TheraRadar
Data updated: May 26, 2026

CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER (clindamycin phosphate)

Dermatology Approved 2012-05-31

CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER is indicated for the treatment of Acne Vulgaris.

Source: FDA Label • Novartis

How CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER Works

The specific process by which this medication works to clear acne vulgaris is currently unknown. It is used to address the condition even though the underlying biological mechanism has not been identified.

Source: FDA Label
3
Indications
--
Phase 3 Trials
13
Years on Market

Details

Status
Prescription
First Approved
2012-05-31
Routes
INJECTION
Dosage Forms
INJECTABLE

Companies

Active Ingredient: CLINDAMYCIN PHOSPHATE

CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER Approval History

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
60 FDA actions from 2012 to 2023
Sep 2023 SUPPL
Label · Labeling
Oct 2022 SUPPL
Label · Labeling
May 2020 SUPPL
Label · Labeling

What CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER Treats

1 indications

CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER is approved for 1 conditions since its original approval in 2012. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Acne Vulgaris
Source: FDA Label

CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ACANYA
BENZOYL PEROXIDE
1 shared
BAUSCH
Shared indications:
ACZONE
DAPSONE
1 shared
ALMIRALL
Shared indications:
ADAPALENE AND BENZOYL PEROXIDE
ADAPALENE
1 shared
PADAGIS ISRAEL
Shared indications:
📋

Clinical Trial Registry

3 trials
Trial Sponsor ID Phase Status Title
NCT04469075 19-342 Ph 2 active not recruiting Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields
NCT04321070 CLPL 1907 Ph 1 completed Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris
NCT00616330 CBC-302-602-622467 Ph 3 completed Vaginal Infection Study
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER FDA Label Details

Indications & Usage

CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER is indicated for the treatment of Acne Vulgaris.

Track CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.